Business Context and Reporting Period
This Form 8-K reports the consummation of a business combination between NorthView Acquisition Corporation and Profusa, Inc. (the "Business Combination") on July 11, 2025. Following the closing, NorthView changed its name to Profusa, Inc. ("New Profusa"), and the former Profusa became a wholly-owned subsidiary. The transaction was accounted for as a reverse capitalization, with the former Profusa deemed the accounting predecessor. New Profusa is a clinical-stage digital health company developing biosensing solutions, including Lumee Oxygen for Critical Limb Ischemia and Lumee Glucose for continuous glucose monitoring.
Key Financial Metrics
Valuation and Capital Structure:
- Equity Valuation: $155,000,000 (adjusted for incentive equity, private placement, and company incentive amounts).
- Share Price Assumption: $10.00 per share.
- Shares Outstanding (Post-Closing): 32,788,877 shares of Common Stock.
- Warrants Outstanding: 17,404,250.
Historical Performance (Three Months Ended March 31, 2025):
- Revenue: $0 (compared to $25,000 in the prior year period).
- Net Loss: $2,716,000 (compared to $2,385,000 in the prior year period).
- Operating Expenses: $1,424,000 (Research & Development: $434,000; General & Administrative: $990,000).
- Cash Flow from Operations: Used $537,000.
- Cash Flow from Financing: Provided $365,000.
- Cash and Equivalents (as of March 31, 2025): Less than $10,000.
Debt and Liquidity:
- Total Contractual Obligations (as of March 31, 2025): $50,248,000, all due within 2025.
- Debt Composition: Includes Senior Notes ($26.6M), Convertible Notes ($19.0M), Tasly Convertible Loan ($2.4M), Promissory Notes ($0.9M), and PPP Loan ($1.4M).
- PIPE Financing: Issued an Initial Note with a principal amount of $10,000,000 for a purchase price of $9,000,000 (10% OID). The note matures 18 months post-closing and bears 10% annual interest.
Material Changes Versus Prior Period
- Revenue Decline: Revenue dropped to zero from $25,000 in the prior year quarter, reflecting a focus on R&D and clinical trials rather than commercial sales.
- Increased Net Loss: Net loss increased by 14% ($331,000) year-over-year, driven primarily by a $150,000 increase in interest expense due to additional senior notes issued.
- Expense Shifts: Research and Development expenses decreased by 14% due to the completion of clinical studies and personnel reductions. Conversely, General and Administrative expenses increased by 19% due to higher audit fees.
- Corporate Status: Transitioned from a private operating company (predecessor) to a public company listed on Nasdaq under the symbol "PFSA."
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy:
Management expects to continue substantial investments in building commercial infrastructure in Europe and the U.S. and developing new products. The company plans to launch Lumee Glucose in Europe in 2025, subject to regulatory approval. Future capital requirements are estimated at approximately $6.0 million to support initial commercialization.
Going Concern Warning:
The filing explicitly states that the company has incurred recurring losses and negative operating cash flows. As of March 31, 2025, cash was less than $0.1 million. Management's plans to obtain additional funds through the Business Combination and PIPE investment are intended to mitigate conditions raising substantial doubt about the company's ability to continue as a going concern within one year. However, the company cannot conclude these plans will be effectively implemented.
Risks and Contingencies:
- Regulatory Approval: Lumee Oxygen requires FDA clearance for U.S. commercialization; Lumee Glucose requires marketing authorization.
- Debt Obligations: Significant debt maturities ($50.2M) are due within 12 months of March 31, 2025. Failure to refinance or raise capital could materially adversely affect operations.
- Market Conditions: Risks include high inflation, tightening financial conditions, and geopolitical instability.
Unusual Items:
- Loss on Fair Value: Recorded a $61,000 loss on the change in fair value of the Tasly Convertible Debt.
- Transaction Costs: Paid $1,500,000 in Business Combination Marketing Fees (with $500,000 deferred) and $1,000,000 to financial advisor HCW.
Investor Verification Checklist
- Debt Maturity Profile: Verify the specific terms and conversion triggers for the $50.2 million in debt obligations due within 12 months of March 31, 2025.
- Going Concern Status: Confirm the sufficiency of the PIPE proceeds ($9M initial note) and other financing to cover the $6.0 million estimated capital requirement for commercialization.
- Regulatory Milestones: Monitor the timeline for FDA clearance of Lumee Oxygen and marketing authorization for Lumee Glucose, as revenue generation is contingent on these approvals.
- Dilution Risks: Review the conversion terms of the PIPE Convertible Notes (conversion price lower of $10 or 95% of VWAP) and the beneficial ownership limitations (4.99% to 9.99%).
- Lock-Up Periods: Note the 8-month lock-up for NorthView Initial Stockholders and varying lock-up periods (6 months to 1 year) for Profusa shareholders.